311 results on '"Koblinski, Jennifer"'
Search Results
2. Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men
3. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma
4. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma
5. Single‐cell transcriptional atlas of human breast cancers and model systems.
6. The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway
7. Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases
8. Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis
9. Anillin is an emerging regulator of tumorigenesis, acting as a cortical cytoskeletal scaffold and a nuclear modulator of cancer cell differentiation
10. High-Dose Acetaminophen with N-acetylcysteine Rescue Inhibits M2 Polarization of Tumor-Associated Macrophages
11. A Comparison of Di- and Trinuclear Platinum Complexes Interacting with Glycosaminoglycans for Targeted Chemotherapy
12. Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
13. Syndecan-1 facilitates breast cancer metastasis to the brain
14. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
15. Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
16. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets
17. Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation
18. Melanoma differentiation associated gene-9/syndecan binding protein promotes hepatocellular carcinoma.
19. Figure S5 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
20. Abstract 670: Sex differences in the innate immune response to lung cancer
21. Abstract 5531: Early detection of cancer disparity and treatment resistance in TNBC
22. Table S1 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
23. Data from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
24. Supplementary Figures from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
25. Data from Urinary-Type Plasminogen Activator Receptor/α3β1 Integrin Signaling, Altered Gene Expression, and Oral Tumor Progression
26. Supplementary Data from Urinary-Type Plasminogen Activator Receptor/α3β1 Integrin Signaling, Altered Gene Expression, and Oral Tumor Progression
27. Supplementary table 3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
28. Figure S1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
29. Supplementary table 1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
30. Supplementary table 2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
31. Supplementary Data from MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
32. Supplementary Figure Legends from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
33. Supplementary Figure 1 from Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
34. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 and Figure S6 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
35. Table S2 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
36. Figure S7 from MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
37. Data from MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
38. Data from Prolyl Isomerase Cyclophilin A Regulation of Janus-Activated Kinase 2 and the Progression of Human Breast Cancer
39. Supplementary Figures 1-4 from Prolyl Isomerase Cyclophilin A Regulation of Janus-Activated Kinase 2 and the Progression of Human Breast Cancer
40. Inhibition of LATS Kinases in Ovarian Cancer Activates Cyclin D1/CDK4 and Decreases DYRK1A Activity
41. Matrigel: From discovery and ECM mimicry to assays and models for cancer research
42. Melanoma differentiation associated gene‐9/syndecan binding protein promotes hepatocellular carcinoma
43. Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
44. S473 Changes in Tumor Micro-Environment With Liquid Nitrogen Spray Cryotherapy and Chemoradiation in Locally Advanced Esophageal Cancer
45. Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
46. Radiation induces ESCRT pathway dependent CD44v3+ extracellular vesicle production stimulating pro-tumor fibroblast activity in breast cancer
47. Limitations of Busulfan to Create Humanize Mice with an Innate Immune System.
48. Abstract 362: MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis
49. Abstract 920: Melanoma differentiation associated gene-9/syndecan binding protein (mda-9/sdcbp): A positive regulator of hepatocellular carcinoma
50. Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.